CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to RHHBY

Ranibizumab (10 mg/mL)

Phase 3
Roche Holding AG (RHHBY)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q2 '27
RHHBYPhase 3

Ranibizumab (10 mg/mL) Phase 3 Est. Readout

Ranibizumab (10 mg/mL)
Q2 2027~Q
CT.gov
00%
Competitive Landscape

1 competitor in Neovascular Age-related Macular Degeneration

View Full Landscape
Drug Information

Target Indication

Neovascular Age-related Macular Degeneration

Clinical Trial

NCT05562947

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.